Influence of the Chemotherapeutic Agent Mitomycin C on In Vitro Dendritic Cell Maturation and Interleukin-12 Production in a Colorectal Cancer Model

Antitumor-targeting drugs can stimulate dendritic cells (DCs) indirectly through the shedding of dying tumor cells as part of what is referred to as a "danger signal". Although chemotherapeutic agents have been shown to kill dendritic cells (DCs), the effects of low, non-cytotoxic doses on...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Iranian journal of immunology Ročník 22; číslo 3; s. 216
Hlavný autor: Mohammed Abdullah, Trefa
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Shiraz Shiraz Institute for Cancer Research 30.09.2025
Predmet:
Antigens, CD - metabolism
Antineoplastic Agents - pharmacology
Antineoplastic drugs
CD11c antigen
CD14 antigen
CD80 antigen
CD83 antigen
CD86 antigen
Cell differentiation
Cell Differentiation - drug effects
Chemotherapy
Coculture Techniques
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - immunology
Colorectal Neoplasms - metabolism
Cytotoxicity
Dendritic cells
Dendritic Cells - drug effects
Dendritic Cells - immunology
Dendritic Cells - metabolism
Drug delivery
Granulocyte-macrophage colony-stimulating factor
HCT116 Cells
Humans
Interleukin 12
Interleukin-12 - metabolism
Mitomycin - pharmacology
Mitomycin C
Monocytes
THP-1 Cells
Tumor cells
Dendritic cell maturation
Mitomycin C
Interleukin-12
Colorectal cancer
In vitro study
ISSN:1735-1383, 1735-367X, 1735-367X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Antitumor-targeting drugs can stimulate dendritic cells (DCs) indirectly through the shedding of dying tumor cells as part of what is referred to as a "danger signal". Although chemotherapeutic agents have been shown to kill dendritic cells (DCs), the effects of low, non-cytotoxic doses on DC function have not been studied. To investigate the impact of various concentrations of mitomycin C at low, non-cytotoxic doses on the maturation of DCs. THP-1 monocytes were differentiated into immature dendritic cells using IL-4 and GM-CSF. HCT116 colorectal cancer cells were treated with mitomycin C at concentrations ranging from 10 to 80 nM and co-cultured with undifferentiated dendritic cells. The expression of co-stimulatory molecules (CD11c, CD80, CD83, CD86, HLA-DR, CD14) and IL-12p70 secretion were measured. Different dosages of Mitomycin C-treated HCT116 cells enhanced the maturation of dendritic cell markers (CD80, CD83, CD86, HLA-DR), but reduced CD14 levels (p< 0.01). While increasing the Mitomycin C dose to 80 nM further upregulated HLA-DR and CD86 expression, the release of IL-12 was highest a 50 nM concentration of mitomycin C (686.7 ± 125.7 pg/mL compared to 263.8 ± 4.8 pg/mL in controls; p < 0.05). IL-12 levels were not significantly increased even with 30 nM Mitomycin C. Low concentrations of Mitomycin C contributed to an increase in dendritic cellmaturation and an increase in the expression of co-stimulatory molecules (CD80, CD86, CD83, and HLA-DR), along with the secretion of cytokines such as IL-12p70, IL-2, and GM-CSF.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1735-1383
1735-367X
1735-367X
DOI:10.22034/iji.2025.106532.3008